Biogenvs.United Therapeutics
BIIB vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.4× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.0 vs 37.2); year to date, Biogen leads (+23.9% vs +5.3%).
Side by side
| BIIB | UTHR | |
|---|---|---|
| Market cap | $31B | $22.3B |
| Price | $220.77 | $518.53 |
| Today | +1.2% | +1.1% |
| Return YTD | +23.9% | +5.3% |
| Return 1Y | +56.6% | +64.3% |
| P/E | 37.2 | 17.0 |
| P/S | 3.1 | 7.1 |
| P/B | 1.6 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More BIIB & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.